UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
University of California, Davis
University of California, Davis
Medicenna Therapeutics, Inc.
University of Michigan Rogel Cancer Center
University of Pittsburgh
University of Virginia
National Institutes of Health Clinical Center (CC)
New Mexico Cancer Research Alliance